Union Health Ministry proposes immediate licence suspension for drug makers if medicines fail critical quality tests

Split-screen image of pharmaceutical medicines displayed on pharmacy shelves alongside a senior Indian political figure, accompanying the Union Health Ministry's proposed immediate licence suspension rules.
Pharmaceutical medicines displayed on pharmacy shelves alongside a senior political figure, in the context of the Union Health Ministry's proposed stricter action against manufacturers of substandard drugs. Representative Image

New Delhi, November 5: Pharmaceutical companies in India could face immediate suspension of manufacturing licences for specific medicines that fail critical quality tests under rules proposed by the Union Health Ministry. The changes aim to help drug regulators act faster against substandard medicines and prevent further manufacturing while quality violations are investigated.

The Ministry of Health and Family Welfare announced the proposed amendments to the Drugs Rules, 1945, on November 4. The draft provisions would allow licensing authorities to suspend the manufacturing licence for a particular drug if it is declared Not of Standard Quality (NSQ) after failing specified critical tests.

Under the existing regulatory process, suspension or cancellation of a manufacturing licence generally involves issuing a show-cause notice to the manufacturer and following prescribed procedures before taking action. According to the ministry, this process can delay regulatory intervention after a medicine has been found to be substandard.

The proposed amendments seek to address that delay by allowing the Central Licensing Approving Authority or the relevant State Licensing Authority to immediately suspend the manufacturing licence for the drug concerned after receiving a Government Analyst’s report confirming failure on specified critical quality parameters.

The proposal identifies five critical parameters: assay, dissolution, related substances, impurities and sterility. These tests assess whether medicines meet prescribed standards for composition, performance, purity and, where applicable, freedom from microbial contamination.

Assay testing checks whether a medicine contains the required amount of its active ingredient. Dissolution testing measures how a medicine releases its active ingredient under specified conditions, while tests for related substances and impurities identify unwanted chemical components. Sterility testing determines whether medicines that must be sterile meet the required standards.

Immediate suspension would apply to failures involving the specified critical parameters rather than every minor deviation from a medicine’s prescribed quality standards.

The proposed rules also introduce conditions for restoring a suspended manufacturing licence. A manufacturer would be required to conduct a root cause analysis to determine why the medicine failed the quality test.

The company would then have to implement corrective and preventive action (CAPA) to address the identified problem and reduce the likelihood of it recurring.

The suspension would remain in place until the manufacturer had completed the required analysis and corrective measures and satisfied the licensing authority that the necessary action had been taken.

The Health Ministry has also proposed changes to Form 13, which contains the Government Analyst’s test report. Under the revised reporting mechanism, information about substandard medicines would be shared with the Drugs Controller General of India (DCGI), the relevant State or Union Territory Licensing Authority, and the manufacturer and marketer of the medicine concerned.

The proposed system is intended to ensure that regulators and companies receive information about quality failures promptly, allowing them to coordinate the necessary regulatory response.

According to the ministry, the amendments follow discussions at the 65th meeting of the Drugs Consultative Committee on December 20, 2024, and recommendations made at the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025.

The government expects the changes to strengthen regulatory oversight of pharmaceutical manufacturing and improve accountability when medicines fail important quality tests.

For patients, the intended benefit is faster action against manufacturers of substandard medicines, potentially reducing the risk of further production of affected drugs.

However, immediate suspension of a manufacturing licence is not the same as an automatic recall of medicines already available in the market. Any action concerning affected batches in circulation would need to follow the applicable regulatory procedures.

The proposed amendments have been issued for public consultation and have not yet become final rules. The ministry has invited objections and suggestions within 30 days from the date on which copies of the Gazette containing the draft rules are made available to the public.

Stakeholders may submit their feedback to the Under Secretary (Drugs), Ministry of Health and Family Welfare, at Kartavya Bhawan-1 in New Delhi, or by email at drugsdiv-mohfw@gov.in.

If finalised and brought into force, the amendments would give drug regulators a faster mechanism to suspend manufacturing licences for specific medicines that fail critical quality tests. Manufacturers would also be required to identify and address the causes of these failures before production could resume.

Read also: ₹2,814 Crore for Lithium and Nickel Processing: India’s Plan to Reduce Dependence on Foreign Suppliers

Read also: ⁠₹80,000 crore investment and 10,000 jobs: Vedanta weighs major power and aluminium expansion in West Bengal